The development of AC5/6 selective activators or inhibitors is still in its infancy, generating novel stimulators and inhibitors or taking advantage of drug repositioning; AC6 gene transfer also holds promise for heart failure treatment. The gene discussed is ADCY5; the disease is heart failure.